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Abstract
Introduction: Outbreaks of hepatitis C virus (HCV) infections among HIV-positive men who have sex with men (MSM) have
been observed globally. Using a multi-modelling approach we estimate the time and number of direct-acting antiviral treatment
courses required to achieve an 80% reduction in HCV prevalence among HIV-positive MSM in the state of Victoria, Australia.
Methods: Three models of HCV transmission, testing and treatment among MSM were compared: a dynamic compartmental
model; an agent-based model (ABM) parametrized to local surveillance and behavioural data (“ABM1”); and an ABM with a
more heterogeneous population (“ABM2”) to determine the influence of extreme variations in sexual risk behaviour.
Results: Among approximately 5000 diagnosed HIV-positive MSM in Victoria, 10% are co-infected with HCV. ABM1 esti-
mated that an 80% reduction in HCV prevalence could be achieved in 122 (inter-quartile range (IQR) 112 to 133) weeks with
523 (IQR 479 to 553) treatments if the average time from HCV diagnosis to treatment was six months. This was reduced to
77 (IQR 69 to 81) weeks if the average time between HCV diagnosis and treatment commencement was decreased to
16 weeks. Estimates were consistent across modelling approaches; however ABM2 produced fewer incident HCV cases, sug-
gesting that treatment-as-prevention may be more effective in behaviourally heterogeneous populations.
Conclusions: Major reductions in HCV prevalence can be achieved among HIV-positive MSM within two years through rou-
tine HCV monitoring and prompt treatment as a part of HIV care. Compartmental models constructed with limited behavioural
data are likely to produce conservative estimates compared to models of the same setting with more complex parametriza-
tions.
Keywords: agent-based model; coinfection; elimination; hepatitis C virus; HIV; men who have sex with men; multi-modelling
Additional Supporting Information may be found online in the Supporting information tab for this article.
Received 6 December 2016; Accepted 18 December 2017
Copyright © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an
open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
1 | INTRODUCTION
Hepatitis C virus (HCV) infection is a leading cause of death
among HIV-positive individuals [1,2]. People living with HIV
have an increased risk of acquiring HCV, in particular through
sexual contact [3]. This is especially the case among HIV-posi-
tive men who have sex with men (MSM) who report engaging
in high-risk sexual behaviour, sometimes but not always in
association with injecting drug use [4,5]. Outbreaks of HCV
infections among MSM have been described in Europe [4–7],
the United States [8], and Australia [9,10]. Once infected,
HIV/HCV co-infected individuals have a reduced chance of
spontaneous clearance [11,12], a more rapid progression to
HCV-related liver disease and increased risk for cirrhosis and
liver cancer [13] compared to people without HIV.
The recent availability of interferon-free direct-acting antivi-
ral (DAA) HCV treatment regimens means that HCV elimina-
tion is now being considered globally [14], with the World
Health Organization announcing 2030 country-level targets of
reducing new chronic HCV infections by 80% and HCV-
related mortality by 65% [15]. Achieving elimination will
require targeted interventions among key populations, and in
particular specific programmes are needed to improve the
currently poor cascade of care [16]. HCV testing and treat-
ment scale-up among HIV-positive MSM is highly achievable
with minimal extra delivery costs given their likely engagement
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with the healthcare system for their HIV care. Recent global
guidelines recommending commencement of HIV treatment
regardless of CD4 count [17] will also enhance the potential
reach of DAA HCV treatments and the feasibility of HCV
elimination efforts in co-infected populations.
Mathematical models are a useful tool for estimating the
feasibility and resources required to achieve HCV elimination
[18,19]. Most modelling studies are restricted by data limita-
tions to the use of compartmental models, which assume
either homogeneous populations and risk behaviours or at
best crudely divide populations into a small number of dis-
crete categories [18]. In reality, the risk of HIV-positive MSM
sexually acquiring or transmitting HCV is complex and related
to HCV testing frequency, consistency of condom use, fre-
quency of sexual partnerships, duration/concurrency of part-
nerships and many other individual characteristics that are
generally either ignored or taken as average values in com-
partmental models. In contrast, agent-based models (ABMs)
are a type of model that can take account of individual-level
characteristics using a set of autonomous “agents” with unique
characteristics to represent a population.
ABMs offer a powerful method for describing complex
human behaviour, as each agent makes decisions about how
to interact with other agents and their environment based on
their individual characteristics. When many agents are com-
bined and simulated together, large scale epidemiological pat-
terns emerge from a multitude of individual behaviours and
stochastic interactions. ABMs are therefore able to answer
questions related to extreme between-individual variations in
risk, and can inform whether these effects warrant considera-
tion in policy-making.
In Victoria, Australia, a unique opportunity exists to parame-
trize an ABM of HCV transmission to the population of HIV-
positive MSM, in which approximately 10% are co-infected
with HCV [20]. The Victorian Primary Care Network on Sen-
tinel Surveillance (VPCNSS) [21] involves automated data
draws of clinical and laboratory testing data from primary
care, sexual health and laboratory service networks around
the state and collects linked risk behaviour data from MSM
testing at high caseload clinics. VPCNSS is capable of linking
clinical and laboratory data on HCV testing to behavioural
data. With this data the distribution of risk (e.g. number of
partners and consistency of condom use) and protective (e.g.
testing frequency) behaviours can be defined and allocated to
agents in the model.
In this paper, we compare three model estimates for the
time and treatment requirements to achieve an 80% reduc-
tion in HCV prevalence among HIV-positive MSM in Victoria:
a simple compartmental model (reflecting what might be esti-
mated if only limited data were available); an ABM parame-
trized by VPCNSS data (reflecting a best estimate using a
more complex parametrization); and an ABM with a more
heterogeneous population (to test how the existence of very
high-risk individuals and behaviours not captured by surveil-
lance systems might impact model estimates). Although the
baseline parameters are aligned with Victorian epidemiological
data, the model will be publically available online (https://
www.openabm.org/model/5234) with population characteris-
tics and treatment access easily modifiable to other settings
globally.
2 | METHODS
2.1 | Setting
Victoria has the second largest number of people living with
HIV in Australia, with the majority living in metropolitan Mel-
bourne; in 2013 there were estimated to be approximately
5000 diagnosed HIV-positive MSM in Victoria [22]. Total HCV
notifications in Victoria have been relatively stable for the per-
iod 2011 to 2014 at between 2200 and 2350 new HCV diag-
noses per year (38 to 41 per 100,000 population) [23];
however a recent increase has been seen in notifications of
HCV in HIV-positive MSM, predominately driven by sexual
transmission [9]. Overall around 2% of Victorian HCV notifica-
tions are estimated to occur among HIV-positive MSM, pre-
dominately through sexual exposure [9]. This would represent
notification rates of HCV in this population of approximately
45 cases per year (1.8 per 100 person-years at risk [20]). In
addition, around 18% of HIV-positive MSM report injecting
drug use [24]. The incidence of HCV through injecting drug
use has been estimated previously at 11.9% per annum in
Australia [25], and hence approximately 48 additional cases
per year could be expected among HIV-positive MSM through
this exposure (assuming a 50% HCV prevalence among people
who inject drugs [26], and therefore that 9% of the 4500
HCV-uninfected are at risk).
A lack of behavioural data prevented the inclusion of
HIV-undiagnosed MSM in our analysis, and henceforward
HIV-positive MSM refers to only those who have been diag-
nosed of their HIV (in Australia an estimated 88% of people
living with HIV have been diagnosed [23]).
2.2 | HCV transmission
In this study, we focussed on the sexual transmission of HCV
among HIV-positive MSM. This was both for the purposes of
understanding the impact of assumptions about sexual net-
works and owing to a lack of detailed epidemiological and
behavioural data on other transmission mechanisms within this
population. However, we accounted for HCV incidence
through other modes using an “HCV import” feature in each
model, which allowed people to become infected from external
sources and through other mechanisms. Imported infections
were used as a method of accounting for transmission
through injecting drug use primarily, but also transmissions
through partnerships between HIV-positive MSM and HIV-
negative MSM (which contribute substantially lower risk of
HCV transmission because of lower HCV prevalence com-
pared to HIV-positive MSM), through partnerships with HIV-
undiagnosed MSM, or through riskier than normal sex when
travelling. The imported infection feature is designed to add
flexibility and has been used in this context elsewhere [27,28].
2.3 | Compartmental model description
We used a dynamic compartmental model to approximate
HCV transmission, diagnosis and treatment among HIV-
positive MSM as shown in Figure 1. The population was cate-
gorized as either: susceptible (i.e. not HCV-infected), acutely
HCV-infected, chronically HCV-infected and not diagnosed,
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chronically HCV-infected and diagnosed, in treatment for
HCV, or failed treatment for HCV. Each compartment was
stratified by high and low levels of risk, with high-risk individu-
als defined as MSM who had more than 10 sexual partners,
participated in group sex or used recreational drugs during
sex in the past six months [29]. High-risk MSM had their risk
of acquiring or transmitting HCV increased by a factor of two
compared to low-risk individuals. A detailed model description
is in the supplementary material, and parameters and their
sources are in Table 1.
Both before and after treatment scale-up HIV-positive
MSM were assumed to have HCV tests as part of their HIV
care. To model treatment scale-up, the average time from
diagnosis to commencing treatment was decreased from
approximately four years to six months. The model was run
for three years post treatment scale-up and the number of
people infected with HCV, HCV incidence and number of
treatments initiated was recorded over time.
2.4 | ABM 1 description
An ABM was constructed in NetLogo [38] and run through R
using the RNetLogo package [39]. It was built by modifying
the existing AIDS model [40] to simulate HCV rather than
HIV transmission dynamics, include different types of sexual
partnerships (described below) and to reflect the characteris-
tics of HIV-positive MSM in Victoria. The complete model is
available from the online repository https://www.openabm.org/
model/5234, and a detailed model description is in the supple-
mentary material. Parameters and their sources are in
Table 2.
The model used weekly time steps and at each step agents
in the model had an HCV status (not infected, infected and
undiagnosed, diagnosed, in treatment), and could interact with
other agents through “regular partnerships” (relationships
lasting more than one time step), “casual partnerships” (each
agent tracks a network of “fuck-buddies”—individuals who
they meet up with for casual sex on more than one occasion),
or “random partnerships” (individuals who they meet up with
for only a single interaction). We allowed a percentage of
agents to not form any casual partnerships, and conversely a
percentage of agents to have concurrent partnerships (ap-
proximating behaviours such as having one or more simultane-
ous partners or participating in group sex).
To account for stochastic variations in the model, multiple
simulations were run. The results of 100 simulations were col-
lated, and plots of the number of people infected with HCV,
HCV incidence and number of treatments initiated was
recorded over time. Median and inter-quartile ranges (IQRs)
from the simulations were compared to the outputs of the
compartmental model, to determine whether more simplistic
models used in data-limited settings are likely to over-
estimate or under-estimate outcomes.
2.5 | ABM 2 description
A second ABM was tested, using the same approach as above
but with alternate population characteristics. In this model,
population heterogeneity and risk were substantially increased
to represent the maximum conceivable values that a sub-
population may have. This was done to determine whether the
presence of extreme heterogeneity and variations in beha-
viours, which may not be captured in surveillance systems, are
likely to impact outcomes. In addition, the second ABM repre-
sents a situation of greater uncertainty and variation in
parameters for comparison with the first (Table 2). Figure 2
compares the distributions for testing frequency, time from
HCV diagnosis to treatment commencement, total number of
casual sex occasions per year and number of casual partners
per year between the first and second ABM populations.
2.6 | Calibration
Each model was calibrated by varying the force of infection to
achieve the desired equilibrium HCV prevalence of 10% [20]
(Figure S2). For the compartmental model, this resulted in a
calibrated incidence rate for the sexual transmission of HCV
(i.e. excluding imported infections) among low- and high-risk
HIV-positive MSM of 0.38% and 0.76% per annum respec-
tively. For the first and second ABMs, this calibration resulted
in “per-casual-hook-up-occasion” HCV transmission probabili-
ties of 1.05% and 0.45% respectively. We were unable to find
any direct estimates of this value elsewhere; however for
comparison the risk of HCV transmission per injecting equip-
ment sharing event has been estimated to be in the range
0.5% to 10% [45–47]. Our calibrated estimates can also be
compared to the transmission probability of HIV per receptive
anal intercourse event, which has been estimated at 1.4%
[48]. Our values for the per-casual-hook-up-occasion sexual
transmission of HCV are therefore higher than estimates for
HIV. This may be due to our measure being an average over
hook-up occasions that may contain varying numbers of sexual
events, and also because the HIV estimates represent an
average for all MSM compared to our model population that
has self-selected as being more likely to engage in higher risk
sexual practices (by virtue of having acquired HIV). Therefore,
Figure 1. Compartmental model schematic.
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an average per-casual-hook-up-occasion HCV transmission
probability among all MSM (HIV-negative and HIV-positive) is
likely to be lower than our calibrated values.
To cross-validate the calibrated models, the proportion of
HCV-infected people in each model who were diagnosed was
compared to available data (Figure S3), and the annual HCV
incidence in each model is shown against available data in
Figure 5 (2015 values).
2.7 | WHO elimination targets
The WHO elimination target aims for an 80% reduction in
HCV incidence at the country level by 2030 [15]; however
notifications among HIV-positive MSM represent only a small
proportion of new infections globally (in Victoria this is
approximately 2% of all notifications [9]). Since we are not
modelling treatment-as-prevention among people who inject
drugs, who represent the largest proportion of notifications
[26], the impact on incidence reduction through a decline in
“imported” infections is not captured by our models. For this
reason a variation in the incidence reduction target was used,
and we measured the time and total treatment numbers
required to achieve an 80% reduction in prevalence among
HIV-positive MSM, in order to mimic a similar reduction in
disease burden in this population. We also compared the
impact of treatment scale-up in the models against the WHO
process targets of achieving 90% of people living with HCV
diagnosed and 80% of people living with HCV on treatment
[15].
2.8 | Basic reproduction number (R0)
The basic reproduction number (R0)—the average number of
new infections caused by one typical infected individual in a
Table 1. Compartmental model parameters
Description Value Source
Population size 5000 Unpublished Victorian surveillance data [22].
HCV prevalence 10% Unpublished Victorian surveillance data [20].
Proportion of HIV-positive MSM who
spontaneously clear HCV infection
15% [30]
Duration of acute stage 12 weeks [31]
Average treatment length 17 weeks 12 weeks for genotype 1 and 2, 24 weeks for genotype 3
[32-35]; assuming the Australian average genotype
distribution (62% genotype 1 and 2, 38% genotype 3 [36])
Treatment success rate 95% For genotype 1 [32-34,37]; assumed equally efficacious across
genotypes.
Force of infection – Calibration parameter
Relative risk of infection for high-risk group 2 Assumed
Proportion at high risk 69% Defined according to STIGMA guidelines [29]. From the Gay
Community Periodic Survey 69% of HIV-positive MSM fit
the high-risk criteria [24].
Importation of infection 3.1% per annum
for high-risk
Assumes that the majority of imported infections are through
injecting drug use. Using an estimated 11.9% probability of
infection per year for people who inject drugs [25], and
assuming that the 18% of HIV-positive MSM who inject
drugs [24] are among the high-risk group, then the annual
probability is
(18% 9 5000 HIV-positive MSM who inject drugs)/
(69% 9 5000 HIV-positive MSM at high risk) 9 (11.9%
probability per year of becoming infected)
Reduction in HCV transmission risk once HCV-
diagnosed
45% Gay Community Periodic Survey [24]: 80% disclosed STI
status to any sex partner, 45% told all of their sex partners.
Testing frequency, prior to treatment scale up
(average times per week)
Once per year Testing frequency coinciding with annual HIV check-ups. Data
does not suggest this differs by risk status.
Average time from diagnosis to commencing HCV
treatment, prior to treatment scale up (weeks)
200 weeks Assumed
Testing frequency, post treatment scale up Once per year Assumed testing frequency to continue as part of HIV care.
Average time from diagnosis to commencing
treatment, post treatment scale up
26 weeks Assumed
The population and behaviours of HIV-positive MSM in Victoria, before and after hypothetical treatment scale-up programmes are implemented.
MSM, men who have sex with men; HCV, hepatitis C virus.
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Table 2. Agent population characteristics and treatment scale-up implementations
Agent property Distribution Source
Agent-based model 1: best representation of Victorian HIV-positive MSM population
Proportion with regular partners 30% Gay Community Periodic Survey [24]: 30% had a
current regular partner
Relationship lengths with regular
partners (weeks)
Gamma (mean = 4.5 years,
variance = 36 years)
Data from Van de Ven et al. [41]: average time in
relationship was a median = 2 years,
mean = 4.5 years (SD of mean = 6.2 years)
Condom use probability with regular
partners
Beta (mean = 19%,
variance = 5%)
Gay Community Periodic Survey [24] for mean;
Authors’ opinion for variance
Condom use probability with casual
partners
Beta (mean = 42%,
variance = 5%)
Gay Community Periodic Survey [24] for mean;
Authors’ opinion for variance
Percent who have casual partners 56% Gay Community Periodic Survey [24]: 56% had a
current casual partner. Likely to be lower bound.
Number of casual partners per year
(for those who have them)
Gamma (mean = 13,
variance = 46)
VPCNSS: 63% of HIV-positive MSM had more than
five casual partners in past six months (extrapolated
to 10 in past 12 months); 15% had more than 10
partners in six months (or 20 in 12 months). These
quantiles were used to back-calculate gamma
distribution parameters [42]
Percent of casual sex with casual
partners (i.e. fuck buddy as opposed
to “random” partners)
95% Authors’ opinion; sensitivity analysis
Frequency of having casual sex (times
per year)
Gamma (mean = 17 9 number of
casual partners, variance = 10)
From Rawstorne et al. [43]: the 100 HIV-positive
MSM who reported having unprotected anal
intercourse with other HIV-positive MSM reported
a total of 2111 acts in the previous six months.
Scaling this up to account for the 42% use of
condoms (see above) gives
2 9 2111/(100 9 0.42) = 101 acts per year.
Assuming a mean of six casual partners per year,
this is approximately 17 hook-ups per casual partner
per year.
Percent who may have concurrent
partners (including group sex)
30% Gay Community Periodic Survey [24]: 30% reported
currently having a regular and a casual partner
concurrently. Likely to be lower bound.
Proportion of HIV-positive MSM who
inject drugs
18% Gay Community Periodic Survey [24]; Mahony et al.
[9]
Probability of importing an infection
through injecting drug use (per week)
0.02% Assumes that the majority of imported infections
are through injecting drug use. Using an estimated
11.9% probability of infection per year for people
who inject drugs [25], the probability per week
found from 0.119 = 1  (1  prob_per_week)^52.
Then assumes 18% of HIV-positive MSM inject
drugs [24].
Reduction in HCV transmission risk
once HCV-diagnosed
45% Gay Community Periodic Survey [24]: 80% disclosed
STI status to any sex partner, 45% told all of their
sex partners. This was implemented with the
assumption that all diagnosed individuals were still
able to transmit but at reduced risk (and assuming
condoms were 100% effective when used).
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completely susceptible population—is an extremely important
value for infectious diseases. Values of R0<1 indicate that the
disease free state is asymptotically stable, and so the disease
is expected to eventually become extinct, while values of
R0>1 indicate that the disease free state is asymptotically
unstable and the disease is able to invade a population [49].
Therefore, we measure the R0 values for each model before
treatment scale-up and the effective reproduction number
(Reff, defined as the R0 value with interventions in place) for
each model after treatment scale-up. Calculation methods for
R0 and Reff are provided in the supplementary material.
2.9 | Study dates
Modelling for this study was undertaken in 2016.
3 | RESULTS
3.1 | Basic reproduction number (R0 and Reff)
Before and after treatment scale-up the compartment model
had R0 and Reff values of 1.15 and 0.42 respectively, the first
ABM had R0 and Reff values of 1.32 (IQR 1.25 to 1.36) and
0.28 (IQR 0.27 to 0.29) respectively, and the second ABM
had R0 and Reff values of 3.34 (IQR 3.28 to 3.41) and 0.66
(IQR 0.65 to 0.68) respectively. In all cases treatment scale-up
reduced R0 from above one to below one, indicating that with
ongoing monitoring and treatment availability a rebound in
new HCV infections would be unlikely.
Since all models were calibrated to the same prevalence,
these findings imply there is an increasing R0 with increasing
heterogeneity. This is consistent with Anderson and May [50],
who found for (compartmental) models with the same R0,
greater heterogeneity led to a lower prevalence and incidence
throughout the course of an HIV epidemic.
3.2 | Time to prevalence reduction
The first ABM estimated that the prevalence of HCV among
HIV-positive MSM in Victoria could be reduced by 80% from
an estimated 10% (approximately 500 HIV-positive MSM) to
below 2% (approximately 100 HIV-positive MSM) in 122 (IQR
112 to 133) weeks if the average time from HCV diagnosis to
treatment were reduced to six months (Figure 3). This was
Table 2. (Continued)
Agent property Distribution Source
Testing frequency HCV (times per
year)
Beta (mean = 1.4,
variance = 0.25)
Burnet Institute (VPCNSS): Hepatitis C Testing and
Infection in HIV-Positive Men in Melbourne, Victoria
[22].
Waiting time from diagnosis to
treatment commencement
Gamma (mean = 200,
variance = 30)
Authors’ opinion, shorter waiting time than the
population average—assumes disease progression
faster for co-infected individuals [13,44], and
patients already engaged in care with some health
literacy as a result of their HIV infection.
Scale-up waiting time from diagnosis to
treatment commencement
Gamma (mean = 26 weeks,
variance = 5)
Assumed
Per act infection probability between
serodiscordant agents
1.18% (IQR 1.10 to 1.21%) Median and inter-quartile range of outcomes from
the calibration procedure.
Agent-based model 2: increased heterogeneity. Where not listed parameters are the same as agent-based model 1.
Percent who have casual partners 90%
Percent who may have concurrent
partners (including group sex)
100%
Number of casual partners per year Gamma (mean = 20,
variance = 46)
Condom use probability with casual
partners
Beta (mean = 10%,
variance = 5%)
Testing frequency Beta (mean = 1.4,
variance = 0.35)
Increased heterogeneity by increasing variance
Waiting time from diagnosis to
treatment commencement
Gamma (mean = 200,
variance = 100)
Increased heterogeneity by increasing variance
Scale-up waiting time from diagnosis to
treatment commencement
Gamma (mean = 26 weeks,
variance = 10)
Increased heterogeneity by increasing variance
Per act infection probability between
serodiscordant agents
0.47% (IQR 0.45 to 0.50%) Median and inter-quartile range of outcomes from
the calibration procedure
Agent-based model 1 is the best representation of Victorian HIV-positive MSM population; and agent-based model 2, which has a more heteroge-
neous population. IQR, inter-quartile range; MSM, men who have sex with men; HCV, hepatitis C virus; VPCNSS, Victorian Primary Care Network
on Sentinel Surveillance.
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similar for the second ABM; however the compartmental
model estimated that it would take approximately 139 weeks
to reduce prevalence by 80%, largely due to the asymptotic
decline in prevalence.
3.3 | Treatment requirements
The first ABM estimated that approximately 523 (IQR 479 to
553) treatments would be required in the first three years of
treatment scale-up to achieve an 80% HCV prevalence reduc-
tion among HIV-positive MSM in Victoria (Figure 4). These
estimates were similar to both the second ABM and the com-
partmental model.
3.4 | WHO diagnosis and treatment targets
For the first ABM, it took three years following treatment
scale-up before 90% of HCV/HIV co-infected MSM were diag-
nosed and four years following treatment scale-up before
80% of HCV/HIV co-infected MSM were treated. For the
second ABM both of these targets were achieved after three
years.
3.5 | Incidence projections
Figure 5 and Figure 6 show the projected annual and cumula-
tive incidence of HCV respectively among HIV-positive MSM in
Victoria over the first three years of treatment scale-up. There
was a substantial difference in expected cumulative incidence
between the models, with increasing heterogeneity resulting in
fewer expected cumulative incident cases. As with the R0 val-
ues, this difference is consistent with Anderson and May [50]:
as the tail of very high-risk individuals increases, so does the
total number of risk acts in a given time period. For example,
this can be seen in Figure 2 bottom-left, which compares the
total number of hook-up occasions (within casual-partner net-
works plus with random partners) between the two ABMs. In
order to calibrate these models to the same observed preva-
lence, a lower transmission probability per hook-up occasion
was therefore required. For the bulk of the population (i.e.
Figure 2. Characteristics of HIV-positive MSM in the two agent-based models (ABMs). ABM1 is based on local surveillance data and best
estimate parameters; ABM2 is a more heterogeneous population. Distribution of testing frequency (times per year; top left), time between
hepatitis C virus (HCV) diagnosis and HCV treatment commencement before treatment scale-up (weeks; top right), the number of casual
hook-ups per year (bottom left, representing the number of times an individual hooks up with either someone in their casual partner net-
work or a random partner) and the number of unique casual partners per year (bottom right). MSM, men who have sex with men.
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those not in the high-risk tail), this meant that the average time
to infection was longer, providing opportunity for a greater
prevalence reduction to occur between expected transmission
events, lowering the risk of acquiring HCV.
Another way of viewing this is that because higher-risk indi-
viduals are more likely to be infected than lower-risk individu-
als, as risk heterogeneity increases in the model, treatments
become increasingly effective for the epidemic because they
become more precisely targeted to those at greatest risk of
transmission. In this sense, although the greater R0 value is
detrimental to the epidemic, it is counterbalanced by an
increased effectiveness of treatment-as-prevention through
risk-targeting. Similar arguments have been considered previ-
ously for models of other infectious diseases [51–53].
3.6 | Sensitivity analysis
A sensitivity analysis for the compartmental model is provided
in the supplementary material (Table S1).
Figure 7 shows the sensitivities of parameters in the first
ABM compared to base estimates for the time and number of
treatments required to reduce HCV prevalence among HIV-
positive MSM to below 2%. The largest deviation in the median
time and number of treatments required from multiple simula-
tions was when condom use with casual partners, the average
time from diagnosis to commencing treatment and the total
population size were varied. The influence of time from diagno-
sis to treatment commencement highlights the importance of
patient follow-up and engagement in HCV care. In particular, if
the average time from HCV diagnosis to treatment commence-
ment could be reduced to 16 weeks, reducing prevalence by
80% was possible in a median of 77 (IQR 69 to 81) weeks with
only 455 (IQR 427 to 482) treatments. Otherwise, outcomes
were fairly robust to changes in behavioural parameters, which
may explain why the confidence intervals for the two ABMs in
Figures 3–6 to were similar in size, despite the second ABM
having more highly skewed behavioural parameter distributions.
A Latin Hypercube uncertainty analysis was conducted to
determine the extent of multivariate uncertainty, and is pro-
vided in the supplementary material (Figure S5).
4 | DISCUSSION
We used multiple modelling techniques to estimate the time
and treatment numbers required to achieve an 80% reduction
in HCV prevalence among HIV-positive MSM in Victoria.
Using an ABM parametrized with local surveillance data and
best available estimates of sexual risk behaviour, this preva-
lence reduction could be achieved in approximately 122 (IQR
112 to 133) weeks with approximately 523 (IQR 479 to 553)
treatment episodes if the average time from HCV diagnosis to
treatment was reduced from approximately four years (pre-
DAAs) to six months (post-DAAs). This is slightly more than
the total number of HCV/HIV co-infected MSM due to the
occurrence of new and re-infections during this period. Fur-
thermore, we found that this prevalence reduction could be
achieved in only 77 (IQR 69 to 81) weeks if the average time
between diagnosis and treatment commencement was
reduced to only 16 weeks.
The influence of time from diagnosis to treatment com-
mencement on HCV transmission in the model highlights the
importance of routine HCV monitoring and education as a
part of HIV care, and rapid treatment commencement for
Figure 3. Projected number of HCV/HIV co-infected MSM in Vic-
toria in the first three years of treatment scale-up. For all models
the average time between HCV diagnosis and treatment com-
mencement after scale-up was reduced to six-months. The solid
black line represents the compartmental model; the darker (dotted)
and lighter (dashed) ribbon graphs represent the median and IQR
for the first ABM (parametrized by surveillance data) and the sec-
ond ABM (a more heterogeneous population) respectively. IQR,
inter-quartile range; MSM, men who have sex with men; HCV, hep-
atitis C virus; ABM, agent-based models.
Figure 4. Projected cumulative number of HCV treatments pro-
vided to HCV/HIV co-infected MSM in Victoria in over the first
three years of treatment scale-up. The solid black line represents
the compartmental model; the darker (dotted) and lighter (dashed)
ribbon graphs represent the median and IQR for the first ABM
(parametrized by surveillance data) and the second ABM (a more
heterogeneous population) respectively. IQR, inter-quartile range;
MSM, men who have sex with men; HCV, hepatitis C virus; ABM,
agent-based models.
Scott N et al. Journal of the International AIDS Society 2018, 21:e25059
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25059/full | https://doi.org/10.1002/jia2.25059
8
those newly diagnosed with HCV. Given the high tolerability
of DAA treatments for HCV and the Australian government’s
commitment of AUS$1 billion over five years for unlimited
and unrestricted DAA treatment access [54–56], rapid com-
mencement of treatment should be possible. Our model sug-
gests that this could have substantial effects on the HCV
epidemic among HIV-positive MSM. Furthermore, although
these models have considered co-infection with HCV, the
importance of monitoring and rapid treatment commencement
is generalizable to other sexually transmitted infections that
have a similar prevalence among this population, for example
syphilis and gonorrhoea.
Compartmental models are typically used to approximate
HCV transmission because data to parametrize network-based
or ABMs is often unavailable for the desired setting. Our mul-
ti-modelling methodology found consistent outcomes between
the compartmental and ABM approaches for the time and
treatment requirements, which supports the use of compart-
ments models for resource allocation decisions. However,
when considering novel approaches to disease control that
may target specific behaviours or individuals, for example net-
work-based treatment approaches [57] or contact tracing
[58], more sophisticated models will be required, as compart-
mental models that approximate these effects have been
shown to break down in these circumstances [59–62].
When an alternate ABM was used, which incorporated
greater uncertainty and more highly skewed transmission risk
behaviours, estimates for the time and treatment numbers
needed to achieve an 80% reduction in prevalence were not
significantly different from the first ABM; however there were
fewer HCV transmission events. This suggests that for two pop-
ulations with the same prevalence, HCV treatment-as-preven-
tion may be more effective in the population with a greater
degree of risk heterogeneity. Given that sexual risk behaviour
among HIV-positive MSM is known to be highly heterogeneous
[43] and data sources may underestimate this heterogeneity
due to limited data capture or reporting bias, estimates of HCV
treatment-as-prevention in this group are likely to be conserva-
tive. This is particularly true of compartmental models which
are generally limited to a small number of discrete risk levels.
Using an ABM to link distributions of behaviour with dis-
ease transmission dynamics we have identified which beha-
viours are most likely to influence HCV transmission and
elimination among HIV-positive MSM. In our model, the fre-
quency and consistency of condom use with casual partners
was associated with the greatest uncertainties in epidemic
predictions. Therefore, obtaining reliable estimates for these
parameters among HIV-positive MSM should be prioritized in
future studies, in particular due to the current paucity of data.
The models used in this study have a number of limitations,
largely due to limitations in their parameter sources and lack
of epidemiological data to inform additional features. First, the
model parameters were derived from a variety of sources that
may not accurately represent all HIV-positive MSM in Victoria.
For this reason we tested alternate modelling methods and
scenarios, in particular of a highly heterogeneous population,
and conducted sensitivity analyses to study the influence of
parameters on HCV transmission and prevalence reduction.
Our projections were consistent using multiple modelling
approaches, providing confidence in our estimates. Second,
this work has been designed to test the impact of different
model assumptions about sexual risk behaviours on the sexual
transmission of HCV. Although we have been able to assess a
number of assumptions, there are many complexities of sexual
Figure 5. Annual incidence of HCV among HIV-positive MSM in
Victoria. Asterisks: data estimates, assuming 2% of Victorian HCV
cases are among HIV-positive MSM through sexual exposure [9],
plus 18% of HIV-positive MSM reporting injecting drug use [24]
with an estimated incidence rate of 11.9% [25]. Circles, triangles
and diamonds: calibrated values (2015) and model projections with
treatment-scale up (2016 to 2018) for the compartmental model,
first ABM (best estimates) and second ABM (heterogeneous esti-
mates) respectively. MSM, men who have sex with men; HCV, hep-
atitis C virus; ABM, agent-based models.
Figure 6. Projected cumulative incidence of HCV among HIV-posi-
tive MSM in Victoria over the first three years of treatment
scale-up. The solid black line represents the compartmental model
cumulative incidence; the darker (dotted) and lighter (dashed)
ribbon graphs represent the median and IQR cumulative incidence
for the first ABM (best estimates) and second ABM (more hetero-
geneous estimates) respectively. IQR, inter-quartile range; MSM,
men who have sex with men; HCV, hepatitis C virus; ABM, agent-
based models.
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behaviour that were not included in the ABMs due to a lack
of epidemiological data; for example changes in casual (“fuck-
buddy”) networks among MSM over time, HCV sero-sorting,
age-assortative mixing and different types of sexual activity
that we were subsequently unable to investigate. Similarly,
due to a lack of injecting network epidemiological data among
this population we could not assess the interaction of sexual
networks with injecting networks. Therefore, we approximated
incidence through injecting networks as a constant flow of
“imported infections”; however in the case of a broader coun-
try-level HCV elimination strategy, treatment-as-prevention
among people who inject drugs may reduce non-sexual HCV
transmission to HIV-positive MSM over time, which would
decrease the time and treatment numbers required to reach
the prevalence reduction target. Informing these gaps in data
is an important area for future work, as our analysis has
shown that different assumptions about transmission net-
works can have important implications. Third, these models do
not include HIV and HCV disease progression or mortality.
Given the time frame being projected was only three years,
changes in disease stage during this period are unlikely to sig-
nificantly impact sexual transmission. Moreover, in Australia
83% of HIV-positive MSM are estimated to be enrolled in
anti-retroviral therapy (ART). This high level of engagement in
Figure 7. Sensitivity of the agent-based model parameters (using ABM1). Median, inter-quartile ranges and ranges of the total treatments
and time required to reduce hepatitis C virus (HCV) prevalence among HIV-positive men who have sex with men in Victoria to 2%. Multiple
simulation runs with alternate parameter estimates for: the percentage of the model population who are able to have concurrent partners;
the percentage of the model population who have one or more casual partners per year; condom use with casual partners; condom use with
regular partners; the percentage of casual sex that occurs with regular-casual partners as opposed to random-casual partners; the reduction
in risk behaviour following HCV diagnosis; the average number of hook-ups with each regular-casual partner per year; the average number
of casual partners per year; the average time between HCV diagnosis and HCV treatment commencement following treatment scale-up; and
the total population size.
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care means that the universal access to DAA treatments for
HCV from 2016 is expected to reduce HCV-related mortality
among this population to be negligible (and possibly zero) over
the time frame considered. It is also possible that MSM who
are on ART have a lower probability of sexually acquiring
HCV; however as parametrization data were not available by
ART status, these effects were averaged as part of the calibra-
tion procedure to obtain population-level forces of infection.
Given that dramatic changes to ART coverage in Australia are
unlikely over the projection period this is not expected to
influence outcomes.
5 | CONCLUSIONS
Major reductions in HCV prevalence can be achieved among
HCV/HIV co-infected MSM within two years. Uncertainties sur-
rounding the distribution of risk behaviours within this popula-
tion are likely to make resource requirement estimates
conservative, as treatment-as-prevention may be more effec-
tive in highly heterogeneous MSM populations. In particular,
compartmental modelling approaches are likely to provide rea-
sonable approximations for settings where detailed behavioural
data are unavailable. Future epidemiological studies should
focus on measuring the frequency and consistency of condom
use with casual partners, as this was the behavioural factor
most likely to influence epidemic projections among MSM.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article:
Figure S1. Compartmental model schematic.
Figure S2. Prevalence of HCV among HIV-positive MSM in
Victoria. Comparison of data estimate to outcomes of the cali-
brated compartmental model, the first ABM (best estimates)
and the second ABM (more heterogeneous estimates). Values
for the ABMs represent medians and inter-quartile ranges of
all simulations.
Figure S3. Proportion of people living with HCV who are diag-
nosed. Comparison of data estimate to outcomes of the cali-
brated compartmental model, the first ABM (best estimates)
and the second ABM (more heterogeneous estimates). Values
for the ABMs represent medians and inter-quartile ranges of
all simulations.
Figure S4. Projected incidence of HCV among HIV-positive
MSM in Victoria over the first three years of treatment scale-
up. The blue and red scatter plots represent median and
inter-quartile ranges (IQRs) of the weekly incidence after mul-
tiple simulations for the first ABM (best estimates) and sec-
ond ABM (more heterogeneous estimates) respectively.
Figure S5. Latin Hypercube uncertainty analysis. Blue boxplots:
Variation in the average (after 10 simulations) time and treat-
ment numbers required to reduce HCV prevalence among
HIV-positive MSM by 80%, as parameters move through points
on the Latin Hypercube. Performed for risk population-related
parameters (proportion who have casual partners, proportion
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who have concurrent partners), frequency-related parameters
(average number of casual partners per year, average number
of hook-ups per fuck buddy per year, percent of casual sex with
partners outside of fuck buddy network), and risk reduction-
related parameters (condom use among casual partners, con-
dom use among regular partners, risk reduction following HCV
diagnosis). Black boxplot: stochastic variation from 100 simula-
tions with point estimate parameters.
Table S1. Sensitivity analysis for the compartmental model.
Impact of alternate parameters on estimates of the time and
treatment numbers required to reduce HCV prevalence
among HIV-positive MSM by 80%
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